Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR

Aurinia Pharmaceuticals Inc.

• Offer price: $6.955 cash per share plus one contingent value right (CVR).
• 5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.
• Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.
• Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.
• CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.